CLINICAL_TRIALS
ClinicalTrials.gov record update
Neoadjuvant Triple Treatment With mFOLFIRINOX, Pembrolizumab and SABR in Patients With (Borderline) Resectable Pancreatic Cancer (PREOPANC-5): a Multicenter Single Arm Phase Ib/II Trial of the Dutch Pancreatic Cancer Group
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06384560
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:25.952255+00:00
- Published At
- 2026-02-13T00:00:00+00:00
- Record Updated At
- 2026-02-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Localized Pancreatic Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Adenocarcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-13"- protocolSection.identificationModule.nctId
"NCT06384560"- protocolSection.identificationModule.officialTitle
"Neoadjuvant Triple Treatment With mFOLFIRINOX, Pembrolizumab and SABR in Patients With (Borderline) Resectable Pancreatic Cancer (PREOPANC-5): a Multicenter Single Arm Phase Ib/II Trial of the Dutch Pancreatic Cancer Group"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.